Skip to main content
. 2022 Jul 16;127(7):1304–1311. doi: 10.1038/s41416-022-01913-4

Fig. 4. Comprehensive assessment of clinical actionability of recurrent late-stage CRCs.

Fig. 4

a Landscape of biomarker-guided drug grouping in late-stage CRCs. The actionable mutations are grouped by their corresponding targeted therapy drug type and broken down by OncoKB level of evidence in CRC. Samples are presented according to their highest level of evidence of actionability. b Upper portion, percentage of samples with a given number of actionable genomic alterations per CRC actionability category. Lower portion, frequencies of actionable alterations in biomarker-guided drug grouping per CRC actionability category. c Percentage summary of actionable categories matched to the data from the OncoKB database.